Biomarker Predicts Immunotherapy Benefit in Head and Neck Cancer but Commercial Path Unclear
Somatic 9p24.1 copy number alterations predicted the degree to which HPV-negative advanced squamous head and neck cancers benefitted from Keytruda and Opdivo.
NCCN Publishes First Guidelines for Pediatric Brain Cancer, Recommends Broad NGS Profiling
The guidelines recognize the importance of molecular profiling in diagnosing, treating, and identifying clinical trial opportunities for children with high-grade gliomas.
Rancho Biosciences Launches Single-Cell Data Science Consortium With Pharma Firms
BMS, J&J, Novartis, and Vesalius will work with the bioinformatics firm to develop standards for creating and using single-cell datasets for drug discovery.
Integrated Tumor, Microbiome Features Influence Immunotherapy Combo Effects in Advanced Melanoma
Gut microbiome features showed ties to treatment response and immune-related adverse events in advanced melanoma patients on a combined checkpoint blockade treatment.
Tempus, Bristol Myers Squibb Expand Cancer Biomarker Alliance
Tempus has been providing Bristol Myers Squibb with de-identified transcriptomic datasets to help in the identification of new cancer biomarkers.